Patents Examined by Samira Jean-Louis
  • Platinum (IV) complexes for use in dual mode pharmaceutical therapy
    Patent number: 9265747
    Abstract: The present invention provides compositions, preparations, formulations, kits, and methods useful for treating subjects in need of therapeutic protocol, including subjects having cancer or at risk of developing cancer. Some embodiments of the invention may comprise a composition comprising a first component comprising a precursor to a therapeutically active platinum agent and a precursor to a second therapeutically active agent. The therapeutically active platinum agent and the second therapeutically active agent may dissociate from each other, thereby forming a first therapeutically active platinum agent and a second therapeutically active agent. The second therapeutically active gent may affect a cellular pathway of a cancer cell and may be substantially inactive towards non-cancerous cells.
    Type: Grant
    Filed: August 26, 2009
    Date of Patent: February 23, 2016
    Assignee: Massachusetts Institute of Technology
    Inventors: Stephen J. Lippard, Shanta Dhar
  • Methods and use of compounds that bind to HER2/neu receptor complex
    Patent number: 9265739
    Abstract: This application describes pharmaceutical compositions, commercial packages, and methods for inhibiting cell proliferative disorders, especially those disorders, including Her2 related cancers, characterized by overactivity and/or inappropriate activity of a receptor tyrosine kinase, and methods for imaging an HER-2 expressing tumor.
    Type: Grant
    Filed: May 26, 2011
    Date of Patent: February 23, 2016
    Assignee: The Trustees Of The University Of Pennsylvania
    Inventors: Mark I. Greene, Ramachandran Murali, Hongtao Zhang
  • Aryl-substituted imidazoles
    Patent number: 9266860
    Abstract: The compounds of the invention are antagonists of MDM2 and MDMX, with excellent specificity for MDM2 and MDMX over other proteins, and with selective binding affinity to MDMX over MDM2. The compounds can therefore regulate p53 activity and treat a variety of cancers. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
    Type: Grant
    Filed: September 30, 2011
    Date of Patent: February 23, 2016
    Assignee: St. Jude Children's Research Hospital
    Inventors: R. Kiplin Guy, Yiqun Zhang, Brandon Young, Michael Dyer, Kristin Finch, Donald Bashford, Nagakumar Bharatham, Richard Kriwacki, Grace Roy-Appa, Lie Min, Jaeki Min, Antonio Ferreira
  • Pyrazolo[3,4-c]pyridine compounds and methods of use
    Patent number: 9260425
    Abstract: Pyrazolo[3,4-c]pyridine compounds of Formula I, including stereoisomers, geometric isomers, tautomers, and pharmaceutically acceptable salts thereof, wherein R1 and R2 are as defined herein, are useful for inhibiting Pim kinase, and for treating disorders such as cancer mediated by Pim kinase. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.
    Type: Grant
    Filed: August 10, 2012
    Date of Patent: February 16, 2016
    Assignee: Genetech, Inc.
    Inventors: Steven Do, Huiyong Hu, Aleksandr Kolesnikov, Wendy Lee, Vickie H. Tsui, Xiaojing Wang, Zhaoyang Wen
  • Method of treatment for mental disorders
    Patent number: 9259423
    Abstract: The invention relates to a medicament or a method for treating mental disorders, in detail, ADHD comprising lurasidone, or a combination of lurasidone and a D4 receptor agonist.
    Type: Grant
    Filed: July 20, 2012
    Date of Patent: February 16, 2016
    Assignee: Sumitomo Dainippon Pharma Co., Ltd.
    Inventors: Kazuhito Ikeda, Takeo Ishiyama
  • Use of transplatin to prevent hearing loss
    Patent number: 9248150
    Abstract: Methods and compositions for treating and preventing toxic side effects of platinum-based chemotherapy agents are disclosed, in which transplatin is administered to a subject. Transplatin is shown to have protective effects against cisplatin-induced ototoxicity, nephotoxicity and neurotoxicity. Anti-inflammatory activity of transplatin is demonstrated and methods and compositions for treating and preventing inflammatory pain are described.
    Type: Grant
    Filed: December 3, 2013
    Date of Patent: February 2, 2016
    Assignee: The Board of Trustees of the Southern Illinois University
    Inventors: Vickram Ramkumar, Debashree Mukherjea, Len Rybak
  • Methods for treatment of diseases and disorders related to transducin ?-like protein 1 (TBL1) activity, including myeloproliferative neoplasia and chronic myeloid leukemia
    Patent number: 9238030
    Abstract: Methods for treatment of diseases and disorders related to transducin ?-like protein 1 (TBL1) activity, including myeloproliferative neoplasia, chronic myeloid leukemia, and acute myeloid leukemia.
    Type: Grant
    Filed: November 6, 2012
    Date of Patent: January 19, 2016
    Assignee: Beta Cat Pharmaceuticals, Inc.
    Inventors: Kapil N. Bhalla, Stephen Horrigan
  • Therapies for hematologic malignancies
    Patent number: 9238070
    Abstract: The invention provides methods that relate to a novel therapeutic strategy for the treatment of hematological malignancies and inflammatory diseases. In particular, the method comprises administration of a compound of formula A, wherein R is H, halo, or C1-C6 alkyl; R? is C1-C6 alkyl; or a pharmaceutically acceptable salt thereof; and optionally a pharmaceutically acceptable excipient.
    Type: Grant
    Filed: February 7, 2013
    Date of Patent: January 19, 2016
    Assignee: Gilead Calistoga LLC
    Inventors: W. Michael Gallatin, Roger G. Ulrich, Neill A. Giese
  • Sulfonamide compounds
    Patent number: 9233946
    Abstract: A compound of formula (I), wherein A is S, O or a double bond, and L is a substituted thiazolyl, phenyl or pyridyl. The compound is useful for the treatment of inflammation and cancer.
    Type: Grant
    Filed: September 19, 2011
    Date of Patent: January 12, 2016
    Assignee: KANCERA AB
    Inventors: Styrbjorn Bystrom, Charles Hedgecock, Evert Homan, Thomas Lundback, Jessica Martinsson, Meral Sari, Katarina Farnegardh, Mattias Jonsson
  • Screening method and compounds for modulating telomerase activity
    Patent number: 9234230
    Abstract: The present invention embraces methods for identifying compounds that modulate the activity of telomerase. Compounds of the invention are identified by designing or screening for a compound which binds to at least one amino acid residue of the TRBD, “thumb,” “finger,” and/or “palm” domain; or FP-pocket, PT-pocket or Th-pocket of telomerase and testing the compound for its ability to modulate the activity of telomerase. Compounds selected for interacting with the T-pocket or Fingers-Palm pocket of telomerase are also provided.
    Type: Grant
    Filed: February 8, 2011
    Date of Patent: January 12, 2016
    Assignee: The Wistar Institute
    Inventor: Emmanuel Skordalakes
  • Inhibition of WDR5 interaction with its binding partners
    Patent number: 9233086
    Abstract: Peptidomimetics that inhibit the interaction between MLL1 and WDR5 are disclosed. Methods of inhibiting MLL1 activity and methods of treating cancers also are disclosed.
    Type: Grant
    Filed: June 14, 2011
    Date of Patent: January 12, 2016
    Assignee: THE REGENTS OF THE UNIVERSITY OF MICHIGAN
    Inventors: Shaomeng Wang, Hacer Karatas, Yali Dou, Elizabeth Townsend, Denzil Bernard
  • Inhibitors of AKT activity
    Patent number: 9221838
    Abstract: The invention relates to a series of compounds with particular activity as inhibitors of the serine-threonine kinase AKT. Also provided are pharmaceutical compositions comprising same as well as methods for treating cancer.
    Type: Grant
    Filed: December 23, 2010
    Date of Patent: December 29, 2015
    Assignee: ALMAC DISCOVERY LIMITED
    Inventors: Lixin Zhang, Graham Peter Trevitt, Hugues Miel, Frank Burkamp, Timothy Harrison, Andrew John Wilkinson, Charles-Henry Fabritius
  • (Poly) aminoacetamide derivatives of epipodophyllotoxin their process of preparation and their applications in therapeutics as anticancer agents
    Patent number: 9216989
    Abstract: The present invention relates to novel podophyllotoxin derivatives substituted in the 4-position by a substituted (poly)aminoalkylaminoacetamide chain, to their process of preparation and to their use as medicament as anticancer agents.
    Type: Grant
    Filed: November 10, 2010
    Date of Patent: December 22, 2015
    Assignee: PIERRE FABRE MEDICAMENT
    Inventors: Thierry Imbert, Yves Guminski, Jean-Marc Barret, Anna Kruczynski
  • Small molecule inhibitors of protein kinases
    Patent number: 9212143
    Abstract: Compounds that modulate, for example, that inhibit, syk kinase, and, optionally other kinases. The compounds can be used to treat a variety of disorders, including inflammatory disorders and autoimmune disorders.
    Type: Grant
    Filed: November 2, 2010
    Date of Patent: December 15, 2015
    Assignee: LEVOLTA PHARMACEUTICALS, INC.
    Inventors: Ketan Desai, Renee Desai
  • Inhibitors of anaphase promoting complex activity
    Patent number: 9205069
    Abstract: The invention provides an anti-proliferative composition comprising a non-peptide analog of the C-terminal isoleucine-arginine (IR) tail motif of an activator of an anaphase promoting complex (APC). The invention further provides methods of inhibiting the ubiquitination activity of the APC by administering compositions of the invention.
    Type: Grant
    Filed: March 8, 2010
    Date of Patent: December 8, 2015
    Assignee: President and Fellows of Harvard College
    Inventors: Randall King, Xing Zeng, Shantanu Gaur
  • 5-anilinoimidazopyridines and methods of use
    Patent number: 9206174
    Abstract: The invention relates to a method of inhibiting abnormal cell growth or treating a hyperproliferative disorder in a mammal comprising administering to said mammal a therapeutically effective amount of an imidazopyridine of formula I with anti-hyperproliferative activity.
    Type: Grant
    Filed: February 5, 2013
    Date of Patent: December 8, 2015
    Assignee: Genentech, Inc.
    Inventor: Robert Heald
  • Methods of treating depression and other related diseases
    Patent number: 9198948
    Abstract: The invention relates to methods for treating depression, anxiety, and other related diseases by administering a peptide NMDAR partial agonist.
    Type: Grant
    Filed: July 9, 2013
    Date of Patent: December 1, 2015
    Assignee: Northwestern University
    Inventor: Joseph Moskal
  • Pharmaceutical compositions and their methods of use
    Patent number: 9186407
    Abstract: The invention relates to a composition comprising a neuronal nicotinic receptor ligand and an ?4?2 positive allosteric modulator, a method of using the same, and a related article of manufacture.
    Type: Grant
    Filed: April 5, 2011
    Date of Patent: November 17, 2015
    Assignee: AbbVie Inc.
    Inventors: Murali Gopalakrishnan, Marie P. Honore, Chih-Hung Lee, John Malysz, Jianguo Ji, Tao Li, Michael R. Schrimpf, Kevin B. Sippy, David J. Anderson
  • Brain, spinal and nerve injury treatment
    Patent number: 9186404
    Abstract: A treatment for brain, spinal and nerve injury comprising use of a substance P receptor antagonist optionally in combination with a magnesium compound. There is also provided a formulation for use in this treatment comprising a substance P receptor antagonist and a magnesium compound.
    Type: Grant
    Filed: June 1, 2009
    Date of Patent: November 17, 2015
    Assignee: EUSTRALIS PHARMACEUTICALS LIMITED
    Inventors: Alan John Nimmo, Robert Vink
  • Fused heteroaryls and their uses
    Patent number: 9181264
    Abstract: Provided are certain fused heteroaryls, compositions thereof and methods of use therefor.
    Type: Grant
    Filed: September 15, 2011
    Date of Patent: November 10, 2015
    Assignee: Hutchison MediPharma Limited
    Inventors: Weiguo Su, Weihan Zhang, Haibin Yang